Sacubitril/valsartan vs enalapril on exercise capacity in patients with heart failure with reduced ejection fraction: A randomized, double-blind, active-controlled study

By dos Santos MR, de Nazaré Nunes Alves MJ, Jordao CP, et al
Published June 5, 2021

Key Takeaways

This study sought to correlate sacubitril/valsartan versus enalapril in patients with heart failure with reduced ejection fraction (HFrEF) based on peak oxygen consumption (VO2) and 6-minute walk test (6-MWT). Researchers enrolled 52 participants with HFrEF with a left ventricular ejection fraction < 40% to receive either sacubitril/valsartan (target dose of 400 mg daily) or enalapril (target dose of 40 mg daily). Via using cardiopulmonary exercise testing, peak VO2 was assessed. They also conducted a six-minute walk test. As per the findings, sacubitril/valsartan did not substantially improve peak VO2 or 6-MWT after 12 or 24 weeks in participants with HFrEF compared with enalapril.

Read the full article on American Heart Journal.

Share with emailShare to FacebookShare to LinkedInShare to Twitter
ADVERTISEMENT